DOP072 Achieving biochemical remission with adalimumab therapy using therapeutic drug monitoring: Results of a large prospective Crohn’s disease cohort

Plevris, N; Jenkinson, Philip; Chuah, Cher Shiong; Lyons, Mathew; Hall, Roanna J.; Jones, G. R.; Watson, Eleanor; Arnott, Ian; Lees, Charlie W.

doi:10.1093/ecco-jcc/jjx180.109

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, there have been few studies (11)(12)(13)(14)(15) (all in adult patients with IBD) examining the relationship between TCs and adverse events, most of these studies have been retrospective [1 prospective (12)], with a sample size similar to ours (range 83-183). In all of these studies the median TC was lower than ours (approximately 7 vs 9 mg/mL).…”

Section: Discussionmentioning

confidence: 99%

“…As a derivative of this change, the question arises as to whether higher doses and higher TC may cause more adverse events in patients. To date, few studies have been published, in adults only, demonstrating no significant association between high TC and adverse events (11–15). Thus, we aimed to examine the relationship between serum anti‐TNFα TCs and noninfusion/injection site reaction related adverse events in children with IBD receiving treatment with infliximab or adalimumab.…”

mentioning

confidence: 99%

See 1 more Smart Citation

High anti‐TNFα Concentrations Are Not Associated With More Adverse Events in Pediatric Inflammatory Bowel Disease

Zvuloni

Matar

Levi

et al. 2021

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

Anti-tumor necrosis factor alpha (anti-TNFa) therapy is commonly used to treat refractory pediatric inflammatory bowel disease (IBD) and carry risks for adverse events. We aimed to assess the relationship between anti-TNFa trough concentrations and adverse events rate among pediatric patients with IBD. The medical records of pediatric patients with IBD who were treated with anti-TNFa agents from 2015 to 2020 and had sequential monitoring of trough concentration (TC) were reviewed retrospectively for the presence of adverse events. The study cohort included 135 eligible patients (59 [43.7%] girls, mean age at diagnosis 12.9 [AE3] years, 111 [82.2%] Crohn disease) who had 1589 measurements of TCs (1037 [63%] infliximab). During a median follow-up period of 1.7 years (IQR 1.1-2.7), we recorded 156 adverse events in 50 patients (37%). Higher TCs were not associated with higher rate of anti-TNFarelated adverse events whereas these events (excluding increase in liver transaminases) were associated with younger age.

show abstract